



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/578,561

03/01/2007

Howard J. Federoff

176/62732 (6-1275)

7894

26774

7590

01/06/2010

NIXON PEABODY LLP - PATENT GROUP
1100 CLINTON SQUARE
ROCHESTER, NY 14604

EXAMINER

KELLY, ROBERT M

ART UNIT

PAPER NUMBER

1633

MAIL DATE

DELIVERY MODE

01/06/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/578,561	Applicant(s) FEDEROFF ET AL.	
	Examiner ROBERT M. KELLY	Art Unit 1633	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 28 October 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 28-31, 33, 34, 49 and 50 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 28-31, 33, 34, 49 and 50 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 10/28/09 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1633

DETAILED ACTION

Applicant's response and amendments of 10/28/09 are entered.

Claims 28, 30, 31, 33, and 34 are presently amended.

Claims 1, 2, 4-7, 9, 12, 16-20, and 22-26 are cancelled.

Claims 49 and 50 are newly presented.

Claims 28-31, 33, 34, 49, and 50 are presently pending.

Election/Restrictions

It is noted that Applicant has cancelled all claims to non-elected inventions, and the newly introduced claims are within the scope of the elected invention, Group IV.

Claims 28-31, 33, 34, 49, and 50 are presently considered.

Specification

The amendment filed 10/28/09 is objected to under 35 U.S.C. 132(a) because it introduces new matter into the disclosure. 35 U.S.C. 132(a) states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: the removal of what Applicant considered to be the essential HSV genes opens up the possible scope to that scope which may exist in the future, and hence, is new matter.

Applicant is required to cancel the new matter in the reply to this Office Action.

Art Unit: 1633

Claim Rejections - 35 USC § 112 - clarity

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

In light of the amendments, the rejections of Claims 28-31, 33, and 34 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, are withdrawn.

To wit, the amendments overcome all bases of lack of clarity.

Claim Rejections - 35 USC § 112 - enablement

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

In light of the amendments, the rejections of Claims 28-31, 33, 34 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement, are withdrawn.

To wit, the claims now no longer administer an amplicon and the various components to form continuing infection.

Claims 28-31, 33, 34, 49, and 50 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 28 contains a limitation to "encode all essential HSV genes". The specification as originally filed teaches that the genes in Figure 3 are those that are known to be "essential", but

Art Unit: 1633

the present amendment to the specification removes such a statement, and relies only upon the Los Alamos National Laboratory internet site, which can change as technology develops. Hence, it is not clear which genes are meant to be encompassed by such limitation due to the amendments.

Claims 29-31, 33, 34, 49, and 50 are rejected for the same basis as Claim 28, because they depend and do not overcome the lack of clarity.

Claim Rejections - 35 USC § 112 – new matter

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 28-31, 33, 34, 49, and 50 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement, for comprising new matter. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The specification has been amended to remove the listing of essential HSV genes, as the present amendment to the paragraph at page 23, line 25, indicates.

However, the claims require “encode all essential HSV genes”.

By removing the limitation as to what Applicant regards as essential HSV genes at the time of invention, Applicant has introduced new matter, because the knowledge in the Art

Art Unit: 1633

changes over time, and hence, what was regarded by Applicant to be essential are not necessarily those that are regarded as essential in the future.

Therefore, the claims are properly rejected for comprising new matter.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 28-31, 33, 34, 49, and 50 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 6,972,127 to Schenk; U.S. Patent No. 6,972,127 to Schenk; U.S. Patent No. 6,946,135 to Schenk; Stavropoulos, et al. (1998) Journal of Virology, 72(9):7137-43; Sacki, et al. (1998) Human Gene Therapy, 9: 2787-94, and as further evidenced by Town, et al. (2002) Journal of Neuroimmunology, 132: 49-59.

Schenk '855 claims methods of treating diseases with Abeta deposits, including Alzheimer's disease, by administration of Abeta to thereby raise antibodies and treating the disease by the antibodies raised (Claims). Schenk '127 claims similar treatments, and teaches in the specification that the peptide may be alternatively delivered via a viral vaccine, wherein the protein is encoded in a vector, which is expressed by the cells, and in one embodiment HSV may be used as the vector, which should be non-pathogenic or attenuated (e.g., Section entitled "III. Therapeutic Agents", subsection entitled "1. Alzheimer's Disease", paragraph 9). Schenk '135 Claims treatment of the same with Abeta linked to a carrier molecule, and teaches in the

Art Unit: 1633

specification that Keyhole limpet hemocyanin and tetanus toxoid may be used (Section entitled “III. Therapeutic Agents”, subsection “1. Alzheimer’s Disease”, subsection entitled “3. Carrier Proteins”).

Stavropoulos and Saeki both discuss the growth of amplicons in the absence of helper virus. Stavropoulos discusses the second-generation packaging system for HSV amplicons, which is centered on the use of five overlapping HSV-1 cosmid clones that together encode the wild-type viral genome but lack the required sequences for cleavage and packaging (p. 7138, col. 1, paragraph 2). Stavropoulos then modified the system by providing a single BAC with all the elements required for replication and packaging of the amplicon, but lacking the viral sequences for cleavage and packaging (e.g., p. 7140, col. 2, paragraph 2-p. 7141, col. 1, paragraph 2). Saeki teaches similar prior art knowledge with regard to the five overlapping HSV-1 cosmid clones for production of helper-free virus amplicons (e.g., p. 2788, paragraph bridging columns) and similar production of a single bacterial artificial chromosome for production of helper-free viral amplicons (p. 2788, col. 2, paragraph 2). Still further, both Stavropoulos and Saeki teach that the amplicons contain nucleic acid sequences encoding an accessory protein for replication in *E. coli* (e.g., Saeki, p. 2787, paragraph bridging columns, reciting the use of antibiotic resistance gene for ampicillin).

With regard to inducing a Th2 mediated immune response, Abeta has been shown by Town to so-induce such a response (e.g., Title), and, absent reason to believe otherwise, the desired effect is there, because any absence of comment does not mean the structure is the same.

Art Unit: 1633

With regard to the presence of a nucleic acid encoding VHS, at least Saeki has nothing that indicates that such gene has been removed, and hence, absent reason to believe otherwise, the nucleic acid may be present in the helper-free virus systems.

Lastly, one may question whether a nucleic acid could provide protein for inducing immune response to the Abeta protein. However, as is shown in Herrlinger, vaccination therapy works, and hence, protein is produced in high enough levels to have an affect (whole article, and discussing previous findings (p.1436).

Hence, it would have been obvious to modify the HSV vectors of Schenk to deliver a gene encoding Abeta and a gene encoding keyhole limpet hemocyanin, and grow such in a helper-free virus method like that of Stavropoulos and Saeki, to then administer the helper-free viral amplicon to treat Alzheimer's disease. The Artisan would do so to treat the disease. Moreover, the Artisan would have a reasonable expectation of success, as Schenk teaches it will work, and claims similar protein therapy, Stavropoulos and Saeki teach the method of amplicon manufacture, and Herrlinger demonstrates the biologically-relevant levels of protein being produced.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1633

Claims 28-31, 33, 34, 49, and 50 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 6,972,127 to Schenk; U.S. Patent No. 6,972,127 to Schenk; U.S. Patent No. 6,946,135 to Schenk; Stavropoulos, et al. (1998) Journal of Virology, 72(9):7137-43; Saeki, et al. (1998) Human Gene Therapy, 9: 2787-94, and as further evidenced by Town, et al. (2002) Journal of Neuroimmunology, 132: 49-59 as applied to claims 28-31, 33, 34, 49, and 50 above, and further in view of Whitley, et al. (1998) Clinical Infectious Diseases, 26: 541-53.

This rejection is made to overcome possible arguments that VHS is actually deleted in the vector systems of Saeki.

While the art in the base rejection appears to make obvious the invention, there is no specific teaching that VHS is actually included in the Saeki vectors, and hence, where above, the Examiner has relied upon the inherent nature to state that absent reason to believe otherwise, here, the Examiner provides the knowledge that VHS may be used in such vector systems.

Whitley teaches VHS (A.K.A.: UL41) degrades all mRNA, but that because viral transcription occurs at a very high rate, viral protein synthesis is less affected than host cell protein synthesis (p. 543, col. 1, point 2).

Hence, the Artisan would be further motivated to include the VHS encoding sequence into the chromosome, or add it separately through another plasmid. The Artisan would do so to shut down host protein synthesis preferentially, and thereby increase the relative production of proteins for amplicon manufacture and packaging. Moreover, the Artisan would have a reasonable expectation of success, as Whitley teaches the known functional consequences of the VHS protein, and there is nothing to question the efficacy of the method.

Conclusion

No claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a).

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROBERT M. KELLY whose telephone number is (571)272-0729. The examiner can normally be reached on M-F, 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1633

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Robert M Kelly/
Primary Examiner, Art Unit 1633